Sharing innovation to inspire action

Trial expanded for patients with lung cancer

post-image
The U.S. Food and Drug Administration (FDA) has approved an expansion of pharmaceutical company Takeda's ALUNBRIG's current trial for lung cancer patients. ALUNBRIG is a selective next-generation tyrosine kinase inhibitor (TKI) designed to target anaplastic lymphoma kinase-positive (ALK+) molecular alterations. It's designed for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer, icluding those with brain metastases. who were previously treated with crizotinib. Long-term results from the Phase 3 ALTA 1L trial showed ALUNBRIG as a superior first-line treatment. |https://www.businesswire.com/news/home/20200522005448/en/U.S.-FDA-Approves-Takeda%E2%80%99s-ALUNBRIG%C2%AE-brigatinib-First-Line
What do you think?

You must be logged in to post a comment.
Comments
Generic placeholder image

By Mel Raassina

25 May 2020

 
8 Like


Related Posts

Healthcare

post-image

Grapes - an edible sunscreen
24 February 2021 by Jenny Morawsk... 0 Comments
 
4 Like

Healthcare

post-image

Copper is the New Silver
22 February 2021 by Jeremy Ungar 0 Comments
 
2 Like

Healthcare

post-image

A weight loss drug repurposed to save lives
16 February 2021 by Lynn Wood 1 Comments
 
2 Like